In vitro studies have demonstrated that tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) or TRAIL antibodies, when combined with sorafenib, synergistically reduce cell growth and increase cell death in solid tumor cell lines, including breast, prostate, colon, liver, and thyroid cancers [108]. The gene discussed is TNFSF10; the disease is thyroid cancer.